| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $5,982,465 | 15 | 100 |
| Chan Mitchell | director | 0 | $0 | 1 | $72,461 | $-72,461 |
| Goldman Jonathan | director | 0 | $0 | 1 | $162,937 | $-162,937 |
| Sullivan Christopher Ryan | Chief Financial Officer | 0 | $0 | 5 | $1.44M | $-1.44M |
| VARKI PAUL | Chief Legal Officer | 0 | $0 | 1 | $1.51M | $-1.51M |
| Doyle Mittie | Chief Medical Officer | 0 | $0 | 7 | $2.79M | $-2.79M |
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Over the last 12 months, insiders at Avalo Therapeutics, Inc. have bought $0 and sold $5.98M worth of Avalo Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avalo Therapeutics, Inc. have bought $4.58M and sold $4.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $6,500 was made by Almenoff June Sherie (director) on 2024‑11‑13.
| 2026-05-28 | Sale | Doyle Mittie | Chief Medical Officer | 679 0.006% | $16.00 | $10,864 | -10.10% | |
| 2026-05-15 | Sale | Doyle Mittie | Chief Medical Officer | 3,000 0.0281% | $18.76 | $56,280 | -15.20% | |
| 2026-05-06 | Sale | VARKI PAUL | Chief Legal Officer | 75,063 0.6145% | $20.17 | $1.51M | -27.77% | |
| 2026-05-06 | Sale | Doyle Mittie | Chief Medical Officer | 106,555 0.8946% | $20.68 | $2.2M | -27.77% | |
| 2026-05-06 | Sale | Chan Mitchell | director | 3,167 0.0294% | $22.88 | $72,461 | -27.77% | |
| 2026-05-06 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 47,000 0.3852% | $20.19 | $948,722 | -27.77% | |
| 2026-05-05 | Sale | Doyle Mittie | Chief Medical Officer | 1,679 0.0146% | $16.00 | $26,864 | -0.39% | |
| 2026-04-30 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 8,457 0.075% | $13.23 | $111,853 | +20.67% | |
| 2026-04-29 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 8,458 0.0743% | $13.09 | $110,736 | +22.16% | |
| 2026-04-06 | Sale | Doyle Mittie | Chief Medical Officer | 3,970 0.0389% | $18.01 | $71,508 | -10.88% | |
| 2026-04-02 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 7,980 0.0725% | $17.15 | $136,823 | -17.91% | |
| 2026-04-01 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 7,979 0.0709% | $16.77 | $133,770 | -12.22% | |
| 2026-04-01 | Sale | Doyle Mittie | Chief Medical Officer | 679 0.0058% | $16.00 | $10,864 | -12.22% | |
| 2026-03-16 | Sale | Doyle Mittie | Chief Medical Officer | 25,492 0.2275% | $16.15 | $411,607 | -9.93% | |
| 2025-11-14 | Sale | Goldman Jonathan | director | 11,367 0.0979% | $14.33 | $162,937 | +6.19% | |
| 2024-11-13 | Almenoff June Sherie | director | 500 0.4267% | $13.00 | $6,500 | -41.08% | ||
| 2024-11-12 | Almenoff June Sherie | director | 500 0.4103% | $12.50 | $6,250 | -38.37% | ||
| 2023-06-27 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 937,404 9.668% | $0.52 | $486,888 | -85.36% | |
| 2023-06-26 | Sale | ARMISTICE CAPITAL, LLC | 10 percent owner | 2.75M 28.7234% | $0.61 | $1.68M | -87.33% | |
| 2023-06-26 | Caissa Capital Management ltd. | 10 percent owner | 1.61M 17.5933% | $0.64 | $1.03M | -87.33% |
| Doyle Mittie | Chief Medical Officer | 47122 0.4172% | $644,157.74 | 0 | 7 | |
| VARKI PAUL | Chief Legal Officer | 3634 0.0322% | $49,676.78 | 0 | 1 | |
| Chan Mitchell | director | 3166 0.028% | $43,279.22 | 0 | 1 | |
| Sullivan Christopher Ryan | Chief Financial Officer | 423 0.0037% | $5,782.41 | 4 | 5 | |
| Goldman Jonathan | director | 0 0% | $0 | 0 | 1 | |
| Boyd Steven | 47576000 421.2459% | $650.36M | 2 | 0 | ||
| Ball Gary Edward | President | 15500000 137.2396% | $211.88M | 1 | 0 | |
| Moscato Robert Jr. | COO | 2592743 22.9566% | $35.44M | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 731458 6.4765% | $10M | 164 | 2 | |
| Greenleaf Peter | Chief Executive Officer | 412500 3.6523% | $5.64M | 1 | 0 | |
| Pedder Simon | Executive Chairman of the Bd | 262734 2.3263% | $3.59M | 2 | 0 | |
| COLA MICHAEL F | Chief Executive Officer | 175746 1.5561% | $2.4M | 1 | 0 | |
| Calias Pericles | Chief Scientific Officer | 52462 0.4645% | $717,155.54 | 2 | 0 | |
| Miller Joseph M | Chief Financial Officer | 48777 0.4319% | $666,781.59 | 2 | 0 | |
| Harrell James Archie Jr | Chief Commercial Officer | 36766 0.3255% | $502,591.22 | 8 | 0 | |
| Marcus Ronald | Chief Medical Officer | 36000 0.3188% | $492,120.00 | 1 | 0 | |
| Wilkins H Jeffrey | Chief Medical Officer | 33373 0.2955% | $456,208.91 | 2 | 0 | |
| Hacksell Uli | director | 20000 0.1771% | $273,400.00 | 2 | 0 | |
| NEIL GARRY ARTHUR | CEO and Chairman of the Board | 13220 0.1171% | $180,717.40 | 6 | 0 | |
| Greenway Schond L. | CFO | 3883 0.0344% | $53,080.61 | 2 | 0 | |
| Phillips Matthew V | Chief Commercial Officer | 1020 0.009% | $13,943.40 | 2 | 0 | |
| Almenoff June Sherie | director | 1000 0.0089% | $13,670.00 | 2 | 0 | <0.0001% |
| Jones Randal | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Caissa Capital Management ltd. | 10 percent owner | 0 0% | $0 | 32 | 0 |
$22,693,451 | 105 | 8.15% | $171.89M | |
$66,137,559 | 49 | 6.29% | $145.75M | |
$16,308,194 | 42 | 117.21% | $137.97M | |
$140,595,157 | 34 | 17.93% | $141.17M | |
$7,147,964 | 34 | 24.77% | $155.52M | |
$18,752,549 | 33 | -28.39% | $149.57M | |
$6,979,075 | 22 | -28.22% | $140.85M | |
$245,302 | 15 | -4.08% | $130.47M | |
$4,701,608 | 14 | -4.34% | $165.17M | |
$515,321 | 12 | -2.55% | $128.98M | |
$344,394 | 8 | -22.26% | $164.64M | |
$99,355,998 | 7 | -65.74% | $143.56M | |
$22,090,972 | 7 | -3.49% | $156.33M | |
$36,049,976 | 5 | -3.82% | $174.75M | |
$32,289,200 | 3 | -5.46% | $174.31M | |
$16,003,671 | 3 | 55.38% | $173.82M | |
Avalo Therapeutics, Inc. (AVTX) | $12,750 | 2 | -39.73% | $154.39M |
$2,857,000 | 2 | -5.23% | $134.82M | |
$86,200 | 1 | -19.57% | $169.77M |
| Increased Positions | 61 | +89.71% | 7M | +44.56% |
| Decreased Positions | 29 | -42.65% | 2M | -15.58% |
| New Positions | 33 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 804,777 | Sold Out |
| Total Postitions | 100 | +47.06% | 20M | +28.98% |
| Bvf Inc/Il | $23,066.00 | 7.53% | 1.36M | +327,207 | +31.83% | 2025-09-30 |
| Orbimed Advisors Llc | $22,965.00 | 7.5% | 1.35M | +382,300 | +39.53% | 2025-09-30 |
| Nantahala Capital Management, Llc | $21,020.00 | 6.86% | 1.24M | +240,000 | +24.12% | 2025-09-30 |
| Point72 Asset Management, L.P. | $17,939.00 | 5.86% | 1.05M | +1M | New | 2025-09-30 |
| Affinity Asset Advisors, Llc | $17,126.00 | 5.59% | 1.01M | +398,345 | +65.53% | 2025-09-30 |
| Caligan Partners Lp | $14,183.00 | 4.63% | 833,333 | +833,333 | New | 2025-09-30 |
| Balyasny Asset Management L.P. | $13,913.00 | 4.54% | 817,436 | +817,436 | New | 2025-09-30 |
| Silverarc Capital Management, Llc | $12,270.00 | 4.01% | 720,922 | +720,922 | New | 2025-09-30 |
| Vanguard Group Inc | $11,789.00 | 3.85% | 692,637 | +525,696 | +314.9% | 2025-09-30 |
| Ra Capital Management, L.P. | $11,284.00 | 3.68% | 662,968 | -270,005 | -28.94% | 2025-09-30 |